Ji Wei, Zhu Xuan-xuan, Tan Wen-feng, Lu Yan
Rheumatism Immunity Department of The First Hospital Affiliated to Nanjing University of Traditional Chinese Medicine.
Chin J Integr Med. 2005 Mar;11(1):15-21. doi: 10.1007/BF02835742.
To observe the clinical effect of Rebixiao granule (RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism.
Ninety repeatedly attacking acute gouty arthritis patients were divided into the treated group (n = 60) and control group (n = 30). The treated group was treated with RBXG, and the control group was treated with Futalin tablets (diclofenac sodium). The baseline treatment including good rest, low purine diet, sufficient water drinking and urine alkalization, etc. was then given to both groups. Hypoxanthine 600 mg/kg and niacin 100 mg/kg was applied to hyperuricemic mice by gastrogavage to establish the animal models.
The clinical effective rate of the treated group was 95.0% and that of the control 90.0%. Good therapeutic effects were won, insignificant difference (P > 0.05)was shown between the two groups. However, the cure rate of the treated group was 26.7% while that of the control group was 10.0%, with significant difference (P < 0.01) shown between them. The treated group had its blood uric acid lowered, which was significantly different (P < 0.05) from that of the control group. The animal experiment indicated that all the three groups treated with different dosages of RBXG, as well as the Ash bark and Smilax glabra rhizome groups had their blood uric acid content reduced in the hyperuricemic mice.
RBXG has a quicker initiation and better treatment effects than sole anti-inflammatory and analgesic agents on the treatment of repeatedly attacking acute gouty arthritis, showing no obvious toxic or adverse reactions and therefore good for long-term administration and likely to be a safe TCM preparation to control the symptoms and reduce the onsets of repeatedly attacking of acute gouty arthritis. The animal experiment shows that both the compound preparation and part of the single ingredients in the recipe have the function of reducing blood uric acid. However, the compound recipe has better therapeutic effects, proving to be superior to single drugs.
观察热痹消颗粒（RBXG）治疗反复发作性急性痛风性关节炎的临床疗效，并通过血尿酸实验研究探讨其治疗机制。
将90例反复发作性急性痛风性关节炎患者分为治疗组（n = 60）和对照组（n = 30）。治疗组给予热痹消颗粒治疗，对照组给予扶他林片（双氯芬酸钠）治疗。两组均给予包括充分休息、低嘌呤饮食、多饮水及碱化尿液等基础治疗。采用灌胃法给予高尿酸血症小鼠次黄嘌呤600 mg/kg和烟酸100 mg/kg以建立动物模型。
治疗组临床有效率为95.0%，对照组为90.0%。两组均取得良好治疗效果，差异无统计学意义（P > 0.05）。然而，治疗组治愈率为26.7%，对照组为10.0%，两组差异有统计学意义（P < 0.01）。治疗组血尿酸降低，与对照组比较差异有统计学意义（P < 0.05）。动物实验表明，不同剂量热痹消颗粒治疗组以及秦皮和土茯苓组均可使高尿酸血症小鼠血尿酸含量降低。
热痹消颗粒治疗反复发作性急性痛风性关节炎起效快，疗效优于单纯抗炎镇痛药，且无明显毒副作用，有利于长期服用，可能是控制急性痛风性关节炎症状、减少复发的安全中药制剂。动物实验表明，该复方制剂及方中部分单味药均有降低血尿酸的作用。但复方组方疗效更佳，证明优于单味药。
